Nivolumab in melanoma: latest evidence and clinical potential by Douglas B. Johnson, Chengwei Peng, Jeffrey A. Sosman

Get full text

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy by Selina K. Wong, Caroline A. Nebhan, Douglas B. Johnson

Get full text

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis by Douglas B Johnson, Julie A Bastarache, Andrea Davis Puente

Get full text

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms by Gwenyth J. Joseph, Douglas B. Johnson, Rachelle W. Johnson

Get full text

1243 High throughput autoantibody screening identifies antigens associated with the development of multiple immune related adverse events in melanoma by Douglas B Johnson, Justin M Balko, Catherine C Fahey

Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis by Nina B. Curkovic, Kun Bai, Fei Ye, Douglas B. Johnson

Get full text

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis by Daniel Y. Wang, Fei Ye, Shilin Zhao, Douglas B. Johnson

Get full text

1246 Immune related adverse events to checkpoint inhibitors are associated with altered regulatory T cell phenotypes and resemble CTLA4-deficient patients by Douglas B Johnson, Katy Beckermann, Jeffrey Rathmell, James Maiarana, Carissa Elonen, Janet Markle

Immune checkpoint inhibitors and their impact on liver enzymes and attenuation by Benjamin C. Park, Aaron X. T. Lee, Fei Ye, Isik Turker, Douglas B. Johnson

Get full text

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients by Chi Yan, Sheau-Chiann Chen, Gregory D. Ayers, Caroline A. Nebhan, Joseph T. Roland, Vivian L. Weiss, Douglas B. Johnson, Ann Richmond

Get full text

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study by Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi, Joe-Elie Salem

Get full text

Cost assessment in melanoma clinical trials: A cross-sectional study by Rachel S. Goodman, MBA, Desmond C. Garner, BS, Stefan Koester, BS, J. Randall Patrinely, Jr., MD, MBA, Anna K. Dewan, MD, Douglas B. Johnson, MD, MSCI

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies by James L Gulley, Harriet Kluger, Hussein Tawbi, Jeffrey Sosman, Paolo A Ascierto, Michael B Atkins, Nikhil I Khushalani, Douglas B Johnson, Timonthy A Yap, Ryan J Sullivan, David Feltquate

Get full text

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade by Chi Yan, Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt, Gregory D. Ayers, Ann Richmond

Get full text

Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Gro... by Bernardo L. Rapoport, Bernardo L. Rapoport, Bernardo L. Rapoport, Vickie R. Shannon, Tim Cooksley, Tim Cooksley, Tim Cooksley, Douglas B. Johnson, Lindsay Anderson, Ada G. Blidner, Gregory R. Tintinger, Ronald Anderson, Ronald Anderson

Get full text

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling by Peter J. Siska, Romany A. N. Johnpulle, Alice Zhou, Jennifer Bordeaux, Ju Young Kim, Bashar Dabbas, Naveen Dakappagari, Jeffrey C. Rathmell, W. Kimryn Rathmell, Alicia K. Morgans, Justin M. Balko, Douglas B. Johnson

Get full text

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations by Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson

Get full text

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance by Violeta Sánchez, Yaomin Xu, Douglas B Johnson, Emily Hodges, Margaret L Axelrod, Justin M Balko, Xiaopeng Sun, Brandie C Taylor, Catherine C Fahey, Jamaal L James, Lindsey N Guerin, Paula I Gonzalez-Ericsson, Melinda E Sanders

Get full text

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy by Jiun-Ruey Hu, Ameet Patel, Shi Huang, Yan Ru Su, Kimberly B. Dahlman, Kelsey Tomasek, Yueli Zhang, Richard T. O’Neil, Jamye F. O’Neal, Isik Turker, Douglas B. Johnson, Joe-Elie Salem, Javid J. Moslehi, Olalekan Oluwole

Get full text

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma by Lisa Zimmer, Serigne Lo, Celeste Lebbe, Olivier Michielin, Ines Pires da Silva, Paolo Antonio Ascierto, Matteo Carlino, Alexander Menzies, Douglas B Johnson, Claudia Trojanello, Georgina Long, Tasnia Ahmed, Clara Allayous, Johanna Mangana, Florentia Dimitriou, Danny Zakria, Camille Gerard

Get full text